Neuren Pharmaceuticals is a biotechnology business based in Australia. Neuren Pharmaceuticals shares (NEU) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Neuren Pharmaceuticals has a trailing 12-month revenue of around $231.9 million. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as Neuren Pharmaceuticals , you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $10.02 - $25.95 |
|---|---|
| 50-day moving average | $20.7664 |
| 200-day moving average | $16.759 |
| Target price | $26.74 |
| PE ratio | 16.2583 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $1.2 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$19.51
| 1 week (2024-04-12) | -6.02% |
|---|---|
| 1 month (2024-03-19) | -4.88% |
| 3 months (2024-01-19) | -16.37% |
| 6 months (2023-10-19) | 69.80% |
| 1 year (2023-04-19) | 37.98% |
|---|---|
| 2 years (2022-04-19) | 402.84% |
| 3 years (2021-04-19) | 1,313.77% |
| 5 years (2019-04-18) | 1,626.55% |
Valuing Neuren Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neuren Pharmaceuticals 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neuren Pharmaceuticals 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Neuren Pharmaceuticals shares trade at around 16x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Neuren Pharmaceuticals 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $199.3 million (£0.0 million).
The EBITDA is a measure of a Neuren Pharmaceuticals 's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $231.9 million |
|---|---|
| Operating margin TTM | 89.4% |
| Gross profit TTM | $2.7 million |
| Return on assets TTM | 85.52% |
| Return on equity TTM | 127.3% |
| Profit margin | 67.72% |
| Book value | 1.612 |
| Market capitalisation | $2.5 billion |
TTM: trailing 12 months
We're not expecting Neuren Pharmaceuticals to pay a dividend over the next 12 months.
Neuren Pharmaceuticals 's shares were split on a 1:20 basis on 20 November 2017. So if you had owned 20 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Neuren Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Neuren Pharmaceuticals shares which in turn could have impacted Neuren Pharmaceuticals 's share price.
Over the last 12 months, Neuren Pharmaceuticals 's shares have ranged in value from as little as $10.02 up to $25.95. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Neuren Pharmaceuticals 's is 1.988. This would suggest that Neuren Pharmaceuticals 's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
ANZ Group Holdings Ltd. Pfd.
AUD101.63
ANZ Group Holdings Ltd. Pfd.
AUD104.30
Challenger Ltd Preferred
AUD105.12
Macquarie Bank Ltd Pref
AUD106.02
Macquarie Group Ltd Pref
AUD105.59
Macquarie Group Limited
AUD106.10
Suncorp Group Ltd Pref
AUD100.70
Westpac Banking Corp Pref
AUD103.15
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Blinklab shares.
Everything we know about the Maverick Minerals IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a flat $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?